-

02:10:38 AM

ZLAB Stock News

ZLAB - Zai Lab Limited

01/28/21 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentations in February Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that senior management from Zai Lab will be presenting in the following upcoming virtual investor conferences in

RHEA-AI

neutral

01/11/21 6:45 AM

Nasdaq : ZLAB

Turning Point and Zai Lab Broaden Collaboration

Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately $336 Million in Potential Milestone Payments and Royalties SAN DIEGO and SHANGHAI and SAN

RHEA-AI

very positive

01/06/21 4:01 PM

Nasdaq : ZLAB

argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China

Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China argenx to receive $75

RHEA-AI

positive

12/30/20 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference

Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will present at the

RHEA-AI

neutral

12/28/20 7:00 PM

Nasdaq : ZLAB

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been included in the updated National Reimbursement Drug List (NRDL) released by China’s National

RHEA-AI

neutral

12/28/20 7:30 AM

Nasdaq : ZLAB

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

- Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties - Zai Lab to join ongoing global trial for CLN-081 SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020

RHEA-AI

very positive

12/16/20 8:15 PM

Nasdaq : ZLAB

fda approval

Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for the treatment of

RHEA-AI

positive

12/01/20 7:30 AM

Nasdaq : ZLAB

management

Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology

Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the appointment of Alan Sandler, M.D., to the newly created position of President, Head of Global

RHEA-AI

very positive

11/10/20 7:00 PM

Nasdaq : ZLAB

Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Cance

All three efficacy endpoints in the global Phase 2 FIGHT trial met pre-specified statistical significance • Median progression-free survival (PFS) improved from 7.4 months in the placebo arm to 9.5 months in the bemarituzumab arm. Hazard ratio (HR) 0.68 (95% CI: 0.44-1.04) p=0.073 • Median overall

RHEA-AI

neutral

10/29/20 7:30 AM

Nasdaq : ZLAB

Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced dosing of the first patient in China in the global POD1UM-101 study evaluating retifanlimab in patients with

RHEA-AI

neutral

Prev 3 4 5 6 7 8 9 10 11 Next

ZLAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zailaboratory.com
Security nameZai Lab Limited - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressPudong
StateShanghai
CityShanghai
Zip201210
CountryChina (Mainland)

About Zai Lab Limited

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.